>>>Medical Oncology
Medical Oncology2019-02-04T09:01:18+01:00

Medical Oncology

The identification of the molecular alterations present in a tumor sample has allowed great advances in the development of medical oncology. The genomic tests obtained from the tumor samples confirm the diagnosis, allow to establish a prognosis and facilitate the selection of the treatment for each patient.

NIMGenetics offers:

OncoNIM® Biomarker
For the identification of somatic mutations.
Prosigna
For evaluate the prognosis in breast cancer.
Single Gene Sequencing
For the identification of somatic mutations.

OncoNIM® Biomarker
Colon and Lung

Gene panel optimized for the detection of point mutations in tumor samples of colorectal or pulmonary origin. The mutational profile is integrated into the OncoNIM® Biomarker database to provide the specialist with relevant information on possible therapeutic options.

The test identifies recurrent mutations in 22 genes selected because they are prognostic and/or predictive markers, or potential therapeutic targets, currently validated or under evaluation in ongoing clinical trials.

Reference: ONC4001
Delivery of results: 21 working days after receipt of sample.

Contact us

OncoNIM® Biomarker
Lung Fusions

NGS panel developed for the detection of fusion genes in lung cancer. Analyzes four genes involved in a total of 24 fusion genes or rearrangements.

The mutational profile is integrated into the OncoNIM ® Biomarker database for its correlation with available treatments and clinical trials.

Reference: ONC4002
Delivery of results: 21 working days from receipt of the sample.

Contact us

OncoNIM® Biomarker
Broad Spectrum

NGS platform for the detection of point mutations in hotspot regions, fusion transcripts and CNVs, through the study of DNA and RNA from solid tumor samples. The mutational profile is integrated into the OncoNIM® Biomarker database to provide the specialist with relevant information on possible therapeutic options.

The test includes 52 genes, widely characterized in the literature and in clinical guidelines, and for which actionable mutations have been described and that approved drugs exist or are in clinical trials.

Reference: ONC
Delivery of results: 21 working days from receipt of sample.

Contact us

Prosigna

Genomic test for establishing the risk of recurrence in women with breast cancer.

Using the NanoString nCounter® Dx technology and the PAM50 genetic signature analysis algorithm, it is the only test that allows classifying the intrinsic subtype of the breast tumor, as well as establishing a risk category based on the probability of recurrence (ROR) at 10 years. To do this, it considers, together with the molecular information, clinical variables such as the tumor size and the lymph node status of the patient.

The reliability of Prosigna is guaranteed:

  • Clinical trials in the US and Spain show that it is a reproducible, accurate and robust test.
  • Genomic study with CE marking and approved by the FDA

When is it indicated?

As a prognostic indicator in postmenopausal women with breast cancer who have undergone mastectomy surgery, or with breast conservation therapy together with regular locoregional treatment, under the following conditions:

  • Patients with hormone receptor-positive tumors and negative lymph nodes in stages I and II, who will be treated with adjuvant endocrine therapy.
  • Patients with hormone receptor-positive tumors and positive lymph nodes in stages II and IIIA, who will be treated with adjuvant endocrine therapy.

Contact us

Single Gene Sequencing

The detection of sequence alterations in certain proto-oncogenes and tumor suppressor genes is routine in the clinical practice of oncological diagnosis.

NIMGenetics makes available to the specialist the study of mutations in the following genes through different sequencing methodologies.

Contact us

Any doubt about Medical Oncology?

Send us a message

I accept the privacy policy

Do you prefer that we call you?